Pain, acute pain, chronic pain, opioid dependence Pain, acute pain, chronic pain, opioid dependence
Conditions
Interventions
We investigate pain and analgesic use in the polytrauma population
Sponsors
Erasmus Universiteit Rotterdam
Eligibility
Age
16 Years to 64 Years
Inclusion criteria
Inclusion criteria: Patients >16 years of ageAdmission to Erasmus Medical Centre for traumatic injury with an injury severity score >=16Hospital stay of at the Erasmus for at least 48 hours
Exclusion criteria
Exclusion criteria: Death upon arrival or within 48 hours after admissionTransfer to another hospital for follow-up carePatients who are, at time of discharge, unable or unwilling to provide informed consent or NRS scores (for any reason e.g. traumatic brain injury, inability to sufficiently understand the Dutch language etc.)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main study parameter - Opioid cessation rates at 12 weeks (yes/no, total duration of opioid use in weeks) | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary study parameters/endpoints Secondary objectives are outlining analgesic use during the entire period from admission until six months post discharge. Data on pain and pain management during admission will include:Involvement of APS in patient care (yes, no, duration in days)Pain measured using the 11-point Numeric Rating Scale (NRS)Severe pain in first week, defined as an NRS>=7 (yes, no, duration in days) or in the case of ICU admission, pain scores during the first week in the ward will be collectedUse of analgesics (type, dose, yes/no, duration in days)Use of locoregional analgesia both perioperatively and during conservative treatment (which type, perioperative of conservative treatment, duration in days)Data on risk factors, pain and pain management at discharge:Opioid and/or co-analgesics prescription at discharge (yes, no, type of opioid, daily dose in MME/mg)Prescription for non-steroidal anti-inflammatory drugs (yes, no, number of days)Pain measured using NRSPain measured using the BPISymptoms of anxiety and depression measured using the HADSCatastrophizing measured using the PCSPresence of neuropathic pain characteristics using the DN4Data on risk factors, pain and pain management at 12 weeks and 6 months post discharge:Opioid and/or co-analgesics use (yes, no, daily dose in MME/mg)Reason for failure to cease opioids (in the case of failure) Paracetamol and/or non-steroidal anti-inflammatory drugs use (yes, no, number of days)Pain measured using NRSPain measured using the BPISymptoms of anxiety and depression measured using the HADSCatastrophizing measured using the PCSPresence of neuropathic pain characteristics using the DN4 (at 12 weeks only)Referral to a chronic pain clinic (yes, no, if so for which symptoms)Patients’ satisfaction with quality of care | — |
Countries
Netherlands
Contacts
Public ContactNDL Hallensleben
Erasmus MC, Universitair Medisch Centrum Rotterdam
Outcome results
None listed